Drug intelligence / Profile preview

RFT1081

Development stage: Preclinical
Lead developer: Raft Pharmaceuticals
Modality: Recombinant Proteins and Enzymes
Administration: Intranasal

Overview

RFT1081 is a recombinant protein biologic being developed by Raft Pharmaceuticals for the treatment of chronic pain. It acts by regulating cholesterol trafficking in the plasma membrane and normalizing clustered, cholesterol-overloaded lipid raft microdomains in inflamed glia and macrophages. This mechanism is designed to address the underlying cellular pathology of chronic pain states, including chemotherapy-induced neuropathic pain, nerve injury-induced neuropathic pain, and migraine. Preclinical studies have demonstrated efficacy in various animal models of these conditions.

Beyond the preview

Go deeper on RFT1081.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RFT1081.

Explore the full profile